AbbVie Contract Manufacturing AbbVie Contract Manufacturing

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai\u2019s Anti-Cancer Agent LENVIMA Receives Orphan Drug Designation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai: EMA Accepts the MAA for Two Additional Indications of Anti Cancer Agent Lenvatinib and Pembrolizumab Combo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADC Therapeutics Announces FDA Approval of ZYNLONTA\u2122 (loncastuximab tesirine-lpyl) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck and Eisai Receive Positive EU CHMP Opinions for KEYTRUDA\u00ae (Pembrolizumab) Plus LENVIMA\u00ae (Lenvatinib) in Two Different Types of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Eisai","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LENVIMA\u00ae (Lenvatinib) Plus KEYTRUDA\u00ae (Pembrolizumab) Approved in Japan for Patients With Unresectable, Advanced or Recurrent Endometrial Carcinoma That Progressed After Cancer Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CStone Announced the Global Multi-Regional Registration Trial of Anti-PD-1 Antibody Nofazinlimab in Combination with Lenvatinib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma Successfully Reached the Prespecified Enrollment Ta","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"BDR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BDR Pharma Launches Generic Lenvatinib for Cancer Patients in India","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals for Lenvatinib Mesylate

    Menu

    Lenvatinib Mesylate

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    INTERMEDIATES

    DOSSIERs // Finished Dosage Forms

    MARKET PLACE

    PATENTS

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              CStone Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CStone Announced the Global Multi-Regional Registration Trial of Anti-PD-1 Antibody Nofazinlimab in Combination with Lenvatinib as First-Line Treatment for Patients with Ad...

              Details:

              CS1003 (nofazinlimab) is a humanized recombinant IgG4 monoclonal antibody targeting human programmed cell death protein 1 (PD-1) being developed in combination with lenvatinib as first-line treatment for patients with advanced hepatocellular carcinoma.

              Lead Product(s): Nofazinlimab,Lenvatinib Mesylate

              Therapeutic Area: Oncology Product Name: CS1003

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 18, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Eisai

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              LENVIMA® (Lenvatinib) Plus KEYTRUDA® (Pembrolizumab) Approved in Japan for Patients With Unresectable, Advanced or Recurrent Endometrial Carcinoma That Progressed After C...

              Details:

              MHLW has approved the combination of LENVIMA (lenvatinib) multiple receptor tyrosine kinase inhibitor Plus KEYTRUDA® (pembrolizumab) anti-PD-1 therapy for the treatment of patients with endometrial carcinoma.

              Lead Product(s): Lenvatinib Mesylate,Pembrolizumab

              Therapeutic Area: Oncology Product Name: Lenvima

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Merck & Co

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 24, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Merck & Co

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Merck and Eisai Receive Positive EU CHMP Opinions for KEYTRUDA® (Pembrolizumab) Plus LENVIMA® (Lenvatinib) in Two Different Types of Cancer

              Details:

              KEYTRUDA plus LENVIMA is the first anti-PD-1 and tyrosine kinase inhibitor combination to demonstrate a survival benefit in advanced endometrial carcinoma patients, and the benefit was shown regardless of mismatch repair status.

              Lead Product(s): Lenvatinib Mesylate,Pembrolizumab

              Therapeutic Area: Oncology Product Name: Lenvima

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Eisai

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 15, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Eisai

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ADC Therapeutics Announces FDA Approval of ZYNLONTA™ (loncastuximab tesirine-lpyl) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

              Details:

              In this trial, LENVIMA plus KEYTRUDA showed a statistically significant and clinically meaningful improvement in the primary endpoints of Progression-Free Survival and Overall Survival as well as the secondary endpoint of Objective Response Rate versus chemotherapy.

              Lead Product(s): Lenvatinib Mesylate,Pembrolizumab

              Therapeutic Area: Oncology Product Name: Lenvima

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 23, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Eisai

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Eisai: EMA Accepts the MAA for Two Additional Indications of Anti Cancer Agent Lenvatinib and Pembrolizumab Combo

              Details:

              The application requesting an indication of lenvatinib in combination with pembrolizumab for RCC is based on the results of the pivotal Phase 3 CLEAR study (Study 307/KEYNOTE-581) for the first-line treatment of patients with advanced RCC.

              Lead Product(s): Lenvatinib Mesylate,Pembrolizumab

              Therapeutic Area: Oncology Product Name: Lenvima

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 30, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Eisai

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Eisai’s Anti-Cancer Agent LENVIMA Receives Orphan Drug Designation

              Details:

              The pivotal Phase 3 Study 309/KEYNOTE-775 evaluated LENVIMA in combination with KEYTRUDA® in patients with advanced endometrial cancer, following at least one prior platinum-based regimen in Japan, the United States, Europe and other countries.

              Lead Product(s): Lenvatinib Mesylate,Pembrolizumab

              Therapeutic Area: Oncology Product Name: Lenvima

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 15, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              BDR Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              BDR Pharma Launches Generic Lenvatinib for Cancer Patients in India

              Details:

              Bdfoie (lenvatinib mesylate), an oral receptor tyrosine kinase inhibitor, launched in India, for the treatment of differentiated thyroid cancer, advanced liver cancer and advanced kidney cancer.

              Lead Product(s): Lenvatinib Mesylate

              Therapeutic Area: Oncology Product Name: Bdfoie

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 21, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Biopharma Group offers CDMO services with expertise in contract R&D for dried products & liquid formulations.
              Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
              Post Enquiry
              POST ENQUIRY